Derma Sciences, Inc. :DSCI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016

Derma Sciences, Inc. reports financial results for the quarter ended June 30, 2016.

We analyze the earnings along side the following peers of Derma Sciences, Inc. – Oculus Innovative Sciences, Inc., Johnson & Johnson, C. R. Bard, Inc., MiMedx Group, Inc., Invacare Corporation, Merit Medical Systems, Inc., Hill-Rom Holdings, Inc. and Vascular Solutions, Inc. (OCLS-US, JNJ-US, BCR-US, MDXG-US, IVC-US, MMSI-US, HRC-US and VASC-US) that have also reported for this period.

Highlights

  • Summary numbers: Revenues of USD 22.21 million, Net Earnings of USD 1.98 million.
  • Gross margins widened from 37.11% to 37.19% compared to the same period last year, operating (EBITDA) margins now -4.68% from -39.08%.
  • Year-on-year change in operating cash flow of 91.69% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
  • Earnings growth from operating margin improvements as well as one-time items.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2015-06-30 2015-09-30 2015-12-31 2016-03-31 2016-06-30
Relevant Numbers (Quarterly)
Revenues (mil) 22.56 22.17 20.25 20.24 22.21
Revenue Growth (%YOY) 7.84 9.91 -11.47 3.82 -1.54
Earnings (mil) -9.29 -8.96 -4.74 -1.76 1.98
Earnings Growth (%YOY) -6.89 20.31 50.45 83.43 121.35
Net Margin (%) -41.17 -40.43 -23.41 -8.68 8.93
EPS -0.36 -0.35 -0.36 -0.07 0.08
Return on Equity (%) -32.53 -33.39 -18.69 -7.1 7.86
Return on Assets (%) -29.15 -29.71 -16.3 -6.15 6.95

Access our Ratings and Scores for Derma Sciences, Inc.


Market Share Versus Profits

Revenues History
Earnings History

DSCI-US‘s change in revenue this period compared to the same period last year of -1.54% is almost the same as its change in earnings, and is about average among the announced results thus far in its peer group, suggesting that DSCI-US is holding onto its market share. Also, for comparison purposes, revenues changed by 9.71% and earnings by 212.79% compared to the immediate last period.

Revenues Growth Versus Earnings Growth


Earnings Growth Analysis

The company’s earnings growth was influenced by year-on-year improvement in gross margins from 37.11% to 37.19% as well as better cost controls. As a result, operating margins (EBITDA margins) rose from -39.08% to -4.68% compared to the same period last year. For comparison, gross margins were 38.08% and EBITDA margins were -6.21% in the last reporting period.

Gross Margin Versus EBITDA Margin


Gross Margin Trend

Companies sometimes sacrifice improvements in revenues and margins in order to extend friendlier terms to customers and vendors. Capital Cube probes for such activity by comparing the changes in gross margins with any changes in working capital. If the gross margins improved without a worsening of working capital, it is possible that the company’s performance is a result of truly delivering in the marketplace and not simply an accounting prop-up using the balance sheet.

Gross Margin History
Working Capital Days History

DSCI-US‘s improvement in gross margin has been accompanied by an improvement in its balance sheet as well. This suggests that gross margin improvements are likely from operating decisions and not accounting gimmicks. Its working capital days have declined to 248.17 days from 318.52 days for the same period last year.

Gross Margin Versus Working Capital Days


Cash Versus Earnings – Sustainable Performance?

DSCI-US‘s change in operating cash flow of 91.69% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.

Operating Cash Flow Growth Versus Earnings Growth


Margins

The company’s earnings growth has also been influenced by the following factors: (1) Improvements in operating (EBIT) margins from -43.54% to -9.12% and (2) one-time items. The company’s pretax margins are now 11.30% compared to -39.64% for the same period last year.

EBIT Margin Versus PreTax Margin
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for Derma Sciences, Inc.


Company Profile

Derma Sciences, Inc. is a medical technology company, focused on wound care. The company operates its business through three segments: Advanced Wound Care and Traditional Wound Care. The Advanced Wound Care segment includes MEDIHONEY, BIOGUARD, AMNIOEXCEL, AMNIOMATRIX, DERMAGRAN, ALGICELL AG, XTRASORB and TCC-EZ. The Traditional Wound Care segment consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. It manufactures and markets adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. The company also offers skin care products, which includes barrier creams and ointments, antibacterial cleansing foams and sprays, shampoos and body washes, hand sanitizers, bath additives, body oils and moisturizers to nursing homes, hospitals, home healthcare agencies and other institutions. Derma Sciences was founded on September 10, 1984 and is headquartered in Princeton.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of DSCI-US.